Earnings ·
Odyssey Therapeutics reported financial results for the second quarter ended June 30, 2026, reporting a net loss of…
ODTXOdyssey Therapeutics, Inc.
Odyssey Therapeutics reported financial results for the second quarter ended June 30, 2026, reporting a net loss of $52.8 million compared to $41.2 million in the prior year period. Research and development expenses increased to $36.2 million from $30.2 million, while general and administrative expenses decreased to $10.5 million from $13.2 million. The company held $433.1 million in cash as of June 30, 2026, which is expected to fund operations into the second half of 2028. Clinically, data from the Phase 2a monotherapy trial of OD-001 was accepted for presentation at United European Gastroenterology Week in October. The company anticipates initiating a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026, alongside plans to file a clinical trial application for its second program, OD-002, by year-end. Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases.